zyngapoker500mfreechips2022| Baicheng Pharmaceutical (301096.SZ): BIOS2207 received clinical trial approval notice
Gelonghui May 12 丨 Baicheng Pharmaceutical (301096zyngapoker500mfreechips2022.SZ) announcedzyngapoker500mfreechips2022Zhejiang Thermo Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received a clinical trial approval notice from the State Food and Drug Administration (NMPA). The bios2207 drug independently developed by the company will conduct clinical trial research. BIOS2207 is indicated for the treatment of adults and children 4 years of age and older with partial seizures (with or without secondary generalized seizures).
Tags：
Recommendations
- crashteamracingnitrofueledyuzu|Sudan dam collapse leaves at least 60 dead, hundreds missing
- onlinecasinowithfreesignupbonusrealmoney|Jordan launches initiative to support amputees in Gaza
- reelpennbattle35000|Feature: Bringing centuries-old tea experience to modern Taipei
- othercryptogames|Across China: Guarding greenery on northeast China's Changbai Mountain
- playslotsforrealmoneynodeposit|Villagers dry agricultural products in county of Yichun, E China
- casinoswithfreeplayfornewmembers|China's Gansu launches support policies for signature beef noodles industry
- firstpersonroulette|Aerial view of Harbin, China's "Ice City"
- pennpursuitthree|Across China: Wetland tourism heats up in China's "ice city"
- crashland|Explainer: China pilots housing pension system to enhance people's living quality
- xplaybetcasinonodepositbonus|Senior CPC official meets Cambodian deputy PM